廣告
香港股市 將收市,收市時間:22 分鐘
  • 恒指

    18,089.98
    +17.08 (+0.09%)
     
  • 國指

    6,478.92
    +14.43 (+0.22%)
     
  • 上證綜指

    2,972.53
    +22.53 (+0.76%)
     
  • 滬深300

    3,480.26
    +22.36 (+0.65%)
     
  • 美元

    7.8097
    +0.0011 (+0.01%)
     
  • 人民幣

    0.9300
    +0.0004 (+0.04%)
     
  • 道指

    39,112.16
    -299.05 (-0.76%)
     
  • 標普 500

    5,469.30
    +21.43 (+0.39%)
     
  • 納指

    17,717.65
    +220.84 (+1.26%)
     
  • 日圓

    0.0486
    -0.0001 (-0.12%)
     
  • 歐元

    8.3491
    -0.0162 (-0.19%)
     
  • 英鎊

    9.8950
    -0.0110 (-0.11%)
     
  • 紐約期油

    81.18
    +0.35 (+0.43%)
     
  • 金價

    2,326.60
    -4.20 (-0.18%)
     
  • Bitcoin

    61,673.82
    +930.53 (+1.53%)
     
  • CMC Crypto 200

    1,278.36
    -5.42 (-0.42%)
     

Biogen in up to $1.8 billion deal as rare diseases take center stage

Illustration shows Biogen logo

(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.

Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ.

The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. The therapy developer plans to conduct late-stage trials.

Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.

廣告

The company is now counting on newer medicines such as a second approved Alzheimer's drug Leqembi, developed with Japanese partner Eisai, as well as Reata's Skyclarys to help drive growth.

The deal consists of $1.15 billion in upfront and up to $650 million in potential payments if felzartamab achieves certain development milestones.

The deal is expected to close in the third quarter, the companies said on Wednesday. HI-Bio is backed by investors such as biotech-focused ARCH Venture Partners and Monograph Capital.

(Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)